DekaBank Deutsche Girozentrale’s Apellis Pharmaceuticals APLS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,000	Closed	-$3.5M	–	1121
2025 Q4	$3.5M	Hold	55,000	–	–	0.01%	652
2025 Q3	$1.2M	Hold	55,000	–	–	﹤0.01%	840
2025 Q2	$921K	Hold	55,000	–	–	﹤0.01%	881
2025 Q1	$1.29M	Hold	55,000	–	–	﹤0.01%	805
2024 Q4	$1.74M	Hold	55,000	–	–	﹤0.01%	777
2024 Q3	$1.57M	Hold	55,000	–	–	﹤0.01%	804
2024 Q2	$2.25M	Hold	55,000	–	–	﹤0.01%	742
2024 Q1	$3.18M	Hold	55,000	–	–	0.01%	668
2023 Q4	$3.43M	Hold	55,000	–	–	0.01%	662
2023 Q3	$2.15M	Buy	+55,000	New	+$2.42M	0.01%	722
2023 Q1	–	Sell	-50,000	Closed	-$2.53M	–	1304
2022 Q4	$2.53M	Hold	50,000	–	–	0.01%	672
2022 Q3	$3.18M	Sell	50,000 -7,700	-13%	-$456K	0.01%	611
2022 Q2	$2.55M	Buy	57,700 +31,000	+116%	+$1.41M	0.01%	672
2022 Q1	$1.32M	Sell	26,700 -16,700	-38%	-$737K	﹤0.01%	854
2021 Q4	$2.04M	Buy	43,400 +18,700	+76%	+$736K	0.01%	768
2021 Q3	$824K	Sell	24,700 -14,000	-36%	-$787K	﹤0.01%	943
2021 Q2	$2.43M	Sell	38,700 -12,000	-24%	-$619K	0.01%	678
2021 Q1	$2.12M	Hold	50,700	–	–	0.01%	683
2020 Q4	$2.77M	Sell	50,700 -11,500	-18%	-$486K	0.01%	594
2020 Q3	$1.78M	Buy	+62,200	New	+$1.86M	0.01%	615
2019 Q3	–	Sell	-134,000	Closed	-$3.28M	–	995
2019 Q2	$3.28M	Buy	+134,000	New	+$2.73M	0.02%	519

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

DekaBank Deutsche Girozentrale's APLS Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 55,000 shares — an estimated $3.5M sold.

DekaBank Deutsche Girozentrale first reported a position in APLS in Q2 2019 and held it in 21 quarters. The position peaked at $3.5M in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 55,000 Apellis Pharmaceuticals shares in Q1 2026, an estimated $3.5M.
DekaBank Deutsche Girozentrale first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 21 quarters.
DekaBank Deutsche Girozentrale's Apellis Pharmaceuticals position peaked at $3.5M in Q4 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.